{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T18:22:59Z","timestamp":1750789379775,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005378","name":"Hacettepe \u00dcniversitesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005378","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00296-021-04939-8","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T16:02:45Z","timestamp":1625500965000},"page":"1915-1924","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0624-1986","authenticated-orcid":false,"given":"Burcu","family":"Yagiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0298-4157","authenticated-orcid":false,"given":"Belkis Nihan","family":"Coskun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7054-5351","authenticated-orcid":false,"given":"Yavuz","family":"Pehlivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8645-2670","authenticated-orcid":false,"given":"Ediz","family":"Dalkilic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2802-6061","authenticated-orcid":false,"given":"Sedat","family":"Kiraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3176-4850","authenticated-orcid":false,"given":"Veli","family":"Yazisiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6577-8129","authenticated-orcid":false,"given":"Orhan","family":"Kucuksahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8084-2018","authenticated-orcid":false,"given":"Abdulsamet","family":"Erden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1185-5816","authenticated-orcid":false,"given":"Nilufer Alpay","family":"Kanitez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3775-639X","authenticated-orcid":false,"given":"Gezmi\u015f","family":"Kimyon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5184-4404","authenticated-orcid":false,"given":"Hakan","family":"Emmungil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0783-1072","authenticated-orcid":false,"given":"Sule Yasar","family":"Bilge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2544-8648","authenticated-orcid":false,"given":"Timucin","family":"Kasifoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1730-2991","authenticated-orcid":false,"given":"Cemal","family":"Bes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3886-2813","authenticated-orcid":false,"given":"Ertugrul Cagri","family":"Bolek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2260-4660","authenticated-orcid":false,"given":"Emre","family":"Bilgin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6725-4182","authenticated-orcid":false,"given":"Ahmet","family":"Karatas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8810-2869","authenticated-orcid":false,"given":"Bahar","family":"Kelesoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6172-7762","authenticated-orcid":false,"given":"Duygu","family":"Ersozlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6990-4206","authenticated-orcid":false,"given":"Emel Orge","family":"Gonullu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1537-2192","authenticated-orcid":false,"given":"Ridvan","family":"Mercan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4691-3417","authenticated-orcid":false,"given":"Sedat","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3443-3117","authenticated-orcid":false,"given":"Omer","family":"Karadag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3734-1242","authenticated-orcid":false,"given":"Servet","family":"Akar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3904-0769","authenticated-orcid":false,"given":"Ihsan","family":"Ertenli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7129-2109","authenticated-orcid":false,"given":"Umut","family":"Kalyoncu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"4939_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Louis Bridges Jr S et al (2016) 2015 American college of rheumatology guidelines for the treatment of rheumatoid arthritis. Arthritis Care Res 68:1\u201325. https:\/\/doi.org\/10.1002\/acr.22783","journal-title":"Arthritis Care Res"},{"key":"4939_CR2","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960\u2013977. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210715","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"4939_CR3","doi-asserted-by":"publisher","first-page":"ii124","DOI":"10.1136\/annrheumdis-2012-202350","volume":"72","author":"Y Tanaka","year":"2013","unstructured":"Tanaka Y (2013) Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal? Ann Rheum Dis 72(Suppl 2):ii124\u2013ii127. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202350","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4939_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40744-017-0089-8","volume":"5","author":"CA Spivey","year":"2018","unstructured":"Spivey CA, Griffith J, Kaplan C et al (2018) A Retrospective analysis of corticosteroid utilization before initiation of biologic DMARDs among patients with rheumatoid arthritis in the United States. Rheumatol Ther 5(1):255\u2013270. https:\/\/doi.org\/10.1007\/s40744-017-0089-8","journal-title":"Rheumatol Ther"},{"key":"4939_CR5","doi-asserted-by":"publisher","first-page":"CD000189","DOI":"10.1002\/14651858.CD000189.pub2","volume":"1","author":"PC Gotzsche","year":"2005","unstructured":"Gotzsche PC, Johansen HK (2005) Short-term low dose corticosteroids vs placebo and nonsteroidal anti-inflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev 1:CD000189. https:\/\/doi.org\/10.1002\/14651858.CD000189.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"4939_CR6","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/BF02231779","volume":"12","author":"MJ van der Veen","year":"1993","unstructured":"van der Veen MJ, Bijlsma JW (1993) The effect of methylprednisolone pulse therapy on methotrexate treatment of rheumatoid arthritis. Clin Rheumatol 12:500\u2013505. https:\/\/doi.org\/10.1007\/BF02231779","journal-title":"Clin Rheumatol"},{"key":"4939_CR7","first-page":"713","volume":"10","author":"ED Harris Jr","year":"1983","unstructured":"Harris ED Jr, Emkey RD, Nichols JE et al (1983) Low dose prednisone therapy in rheumatoid arthritis: a double-blind study. J Rheumatol 10:713\u2013721","journal-title":"J Rheumatol"},{"issue":"142","key":"4939_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJM199507203330302","volume":"333","author":"JR Kirwan","year":"1995","unstructured":"Kirwan JR (1995) The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The arthritis and rheumatism council low-dose glucocorticoid study group. N Engl J Med 333(142):146. https:\/\/doi.org\/10.1056\/NEJM199507203330302","journal-title":"N Engl J Med"},{"key":"4939_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-136-1-200201010-00006","volume":"136","author":"AA van Everdingen","year":"2002","unstructured":"van Everdingen AA, Jacobs JWG, Siewertsz DR, Reesema V et al (2002) Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 136:1\u201312. https:\/\/doi.org\/10.7326\/0003-4819-136-1-200201010-00006","journal-title":"Ann Intern Med"},{"issue":"1","key":"4939_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s13075-017-1461-3","volume":"19","author":"RJ Black","year":"2017","unstructured":"Black RJ, Lester S, Buchbinder R et al (2017) Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: a drug use study from a prospective national biologics registry. Arthritis Res Ther 19(1):253. https:\/\/doi.org\/10.1186\/s13075-017-1461-3","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"4939_CR11","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41584-018-0079-4","volume":"14","author":"R Hardy","year":"2018","unstructured":"Hardy R, Cooper MS (2018) Unravelling how glucocorticoids work in rheumatoid arthritis. Nat Rev Rheumatol 14(10):566\u2013567. https:\/\/doi.org\/10.1038\/s41584-018-0079-4","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"4939_CR12","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4939_CR13","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73(3):492\u2013509. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204573","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4939_CR14","doi-asserted-by":"publisher","first-page":"856","DOI":"10.3906\/sag-1807-200","volume":"48","author":"U Kalyoncu","year":"2018","unstructured":"Kalyoncu U, Ta\u015fc\u0131lar EK, Ertenli A\u0130 et al (2018) Methodology of a new inflammatory arthritis registry: TReasure. Turk J Med Sci 48(4):856\u2013861. https:\/\/doi.org\/10.3906\/sag-1807-200","journal-title":"Turk J Med Sci"},{"key":"4939_CR15","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1136\/ard.61.8.71872210.1136\/ard.61.8.718","volume":"61","author":"F Buttgereit","year":"2002","unstructured":"Buttgereit F, da Silva JAP, Boers M et al (2002) Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 61:718\u2013722. https:\/\/doi.org\/10.1136\/ard.61.8.71872210.1136\/ard.61.8.718","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4939_CR16","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","volume":"76","author":"S Ramiro","year":"2017","unstructured":"Ramiro S, Sepriano A, Chatzidionysiou K et al (2017) Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 76(6):1101\u20131136. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210708","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4939_CR17","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1136\/annrheumdis-2016-210713","volume":"76","author":"JL Nam","year":"2017","unstructured":"Nam JL, Takase-Minegishi K, Ramiro S et al (2017) Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 76(6):1113\u20131136. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210713","journal-title":"Ann Rheum Dis"},{"key":"4939_CR18","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","volume":"75","author":"C Strehl","year":"2016","unstructured":"Strehl C, Bijlsma JWJ, de Wit M et al (2016) Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate the implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis 75:952\u2013957. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208916","journal-title":"Ann Rheum Dis"},{"key":"4939_CR19","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s00296-015-3229-x","volume":"35","author":"K Albrecht","year":"2015","unstructured":"Albrecht K, Callhoff J, Schneider M et al (2015) High variability in glucocorticoid starting doses in patients with rheumatoid arthritis: observational data from an early arthritis cohort. Rheumatol Int 35:1377\u20131384. https:\/\/doi.org\/10.1007\/s00296-015-3229-x","journal-title":"Rheumatol Int"},{"key":"4939_CR20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/RHU.0b013e31826d6610","volume":"18","author":"MH Cardiel","year":"2012","unstructured":"Cardiel MH, Pons-Estel BA, Sacnun MP et al (2012) Treatment of early rheumatoid arthritis in a multinational inception cohort of Latin American patients: the GLADAR experience. J Clin Rheumatol 18:327\u2013335. https:\/\/doi.org\/10.1097\/RHU.0b013e31826d6610","journal-title":"J Clin Rheumatol"},{"key":"4939_CR21","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1093\/rheumatology\/kes079","volume":"51","author":"E McKeown","year":"2012","unstructured":"McKeown E, Bykerk VP, De Leon F et al (2012) Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort. Rheumatol (Oxf) 51:1662\u20131669. https:\/\/doi.org\/10.1093\/rheumatology\/kes079","journal-title":"Rheumatol (Oxf)"},{"issue":"11","key":"4939_CR22","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1136\/annrheumdis-2016-210135","volume":"76","author":"C Roubille","year":"2017","unstructured":"Roubille C, Rincheval N, Dougados M et al (2017) Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort. Ann Rheum Dis 76(11):1797\u20131802. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210135","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4939_CR23","doi-asserted-by":"publisher","first-page":"339.e1","DOI":"10.1016\/j.amjmed.2015.08.021","volume":"129","author":"THK Puar","year":"2016","unstructured":"Puar THK, Stikkelbroeck NMML, Smans LCCJ et al (2016) Adrenal crisis: still a deadly event in the 21st century. Am J Med 129(3):339.e1\u20139. https:\/\/doi.org\/10.1016\/j.amjmed.2015.08.021","journal-title":"Am J Med"},{"key":"4939_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18102201","author":"RM Paragliola","year":"2017","unstructured":"Paragliola RM, Papi G, Pontecorvi A et al (2017) Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms18102201","journal-title":"Int J Mol Sci"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04939-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-021-04939-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04939-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T10:16:10Z","timestamp":1632996970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-021-04939-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["4939"],"URL":"https:\/\/doi.org\/10.1007\/s00296-021-04939-8","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"type":"print","value":"0172-8172"},{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"assertion":[{"value":"3 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"UK received honorary from Abbvie, Amgen, Johnson and Johnson, MSD, Novartis, Pfizer, Roche, UCB. YP received honorary from Abbvie, Roche, Novartis, MSD, Pfizer. TK received honorary from Abbvie, Amgen, MSD, Novartis, Pfizer, Roche, UCB. GK received honorary from Abbvie, Amgen, Novartis, Pfizer, UCB. OK received honorary from Amgen, Johnson and Johnson, MSD, Novartis, Pfizer, Roche, UCB. ED received honorary from Abbvie, Amgen, Johnson and Johnson, MSD, Novartis, Pfizer, Roche, UCB. IE received honorary from Abbvie, Amgen, Johnson and Johnson, MSD, Novartis, Pfizer, Roche, UCB. SK received honorary from Abbvie, Amgen, MSD, Novartis, Pfizer, Roche, UCB. DE received honorary from Abbvie, Amgen, MSD, Novartis, Pfizer, UCB. CB received honorary from Abbvie, Amgen, MSD, Novartis, Pfizer, Roche, UCB. HE received honorary from Novartis, Roche. RM received honorary from Abbvie, Amgen, MSD, Novartis, Pfizer, Roche, UCB. NK received honorary from Novartis, UCB. SY received honorary from Abbvie, Amgen, Johnson and Johnson, MSD, Novartis, Pfizer, Roche, UCB. Other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of \u0131nterest"}},{"value":"To perform the present research, the approval for the TReasure database was obtained from the Ethics Committee of Hacettepe University in May 2017 (KA17\/058) and from the Republic of Turkey Ministry of Health in October 2017 (93189304-14.03.01).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent of all patients was obtained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}